Physician profile
Punit K Jain
NPI 1205984051
$2,429.40
in general payments reported to CMS, 2019-2025
13 companies · $551 in 2025
The $551 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $30.54 · 2021: $252 · 2022: $234 · 2023: $335 · 2024: $552 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,416 · Consulting Fee: $20.00 · Education: $2.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,415.80 |
| Consulting Fee | $20.00 |
| Education | $2.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $785.26 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Alcon Vision LLC | $438.96 | 2019-2025 | Precision7, Precision 1, Total30 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $300.56 | 2019-2021 | |
| Coopervision INC. | $227.26 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $142.77 | 2019 | |
| Abbvie INC. | $138.56 | 2022 | |
| Amgen INC. | $121.13 | 2024 | |
| Biotissue Holdings INC. | $84.10 | 2025 | |
| Allergan, INC. | $77.85 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $43.00 | 2022-2024 | |
| Visioneering Technologies, INC. | $32.99 | 2021-2022 | |
| Sight Sciences, INC. | $18.49 | 2019 | |
| Carl Zeiss Meditec, INC. | $18.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Punit Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.